JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…
Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight…
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM,…
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company…
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics…
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will…
CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated,…
PALO ALTO, CA / ACCESS Newswire / October 21, 2025 / Bioz, Inc., a pioneering AI platform changing the way…
VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience…
Black Book survey reveals just 1 in 4 hospitals can fully exchange patient data across national boundaries in Q4 2025…